Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia

doi:10.4239/wjd.v13.i12.1154

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3470)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

185

WORD

HTML

1518

Figures (1-2)

332

Tables (1-5)

346

Sum=2403

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

291

Download

776

Sum=1067

Dec 15, 2022 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Dec 15, 2022; 13(12): 1154-1167
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1154

Table 1 Clinical and demographic characteristics of patients with type 2 diabetes, with and without coronavirus disease 2019 infection

	Patients without COVID-19 infection, n = 144	Patients with COVID-19 infection, n = 65	P value
Age (yr), mean (SD)	63.9 (9.9)	59.8 (9.2)	0.005¹
Median (IQR)	65 (57-71)	61 (53-66)	0.005¹
Sex, female, n (%)	50 (34.7)	32 (49.2)	0.066²
Population group, n (%)			0.067²
Jews	63 (44.7)	20 (30.8)
Arabs	78 (55.3)	45 (69.2)
BMI (kg/m²), mean (SD)	30.7 (5.9)	32.1 (4.6)	0.09¹
Median (IQR)	30.3 (27.4-33.8)	31.6 (29.1-34.7)	0.09¹
Diabetes duration (yr), median (IQR)	13 (8-17.8)	10 (5.5-14.5)	0.031³
eGFR (mL/min/1.73 m² body surface area) at baseline, median (IQR)	85.4 (62.2-97.6)	91.9 (75.3-101.0)	0.033³
HbA1c (%), median (IQR)	7.6 (6.5-9.1)	7.4 (6.6-9.1)	1.00³
Metformin, n (%)	110 (76.9)	56 (86.2)	0.14²
DPP-4 inhibitors, n (%)	29 (20.1)	18 (27.7)	0.28²
Sulfonylurea, n (%)	8 (5.6)	7 (10.8)	0.25⁴
SGLT2 inhibitors, n (%)	36 (25.0)	18 (27.7)	0.73²
GLP-1 agonists, n (%)	25 (17.4)	12 (18.5)	1.00²
Basal insulin, n (%)	60 (41.7)	18 (27.7)	0.064²
Prandial insulin, n (%)	30 (21.0)	6 (9.2)	0.047²
Current smoking, n (%)	48 (33.3)	4 (6.2)	< 0.001²
No albuminuria, n (%)	65 (45.1)	45 (69.2)	0.002²
Albuminuria < 30 mg/g, n (%)	79 (54.9)	20 (30.8)	0.005³
Albuminuria 30-300 mg/g, n (%)	65 (45.1)	14 (21.5)
Albuminuria > 300 mg/g, n (%)	14 (9.7)	6 (9.2)
Retinopathy, n (%)	21 (21.4)	7 (15.2)	0.50²
NLR_max at hospitalization, median (IQR)	4.0 (2.5-7.8)	6.5 (2.6-10.0)	0.12³
CRP (mg/L) at admission, median (IQR)	9.7 (4.8-45.4)	71.8 (12.2-145.9)	< 0.001³
CRP_max (mg/L) at hospitalization, median (IQR)	11.3 (5.2-68.1)	86.6 (12.2-167.6)	< 0.001³
eGFR (mL/min/1.73 m² body surface area) at hospitalization, median (IQR)	86.0(62.2-96.0)	92.1(76.2-100.8)	0.030³
Albumin, median (IQR)	3.8 (3.4-4.0)	3.6(3.2-3.9)	0.026¹

¹Independent sample t-test.

²Chi-square test.

³Mann-Whitney test.

⁴Fisher’s exact test.

COVID-19: Coronavirus disease 2019; IQR: Interquartile range; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; eGFR: Estimated glomerular filtration rate; DPP-4: Dipeptidyl-peptidase 4; SGLT2: Sodium/glucose cotransporter 2; GLP-1: Glucagon-like peptide 1; NLR_max: Maximum neutrophil:lymphocyte ratio; CRP: C-reactive protein; CRP_max: Maximum C-reactive protein.

Table 2 Clinical and demographic characteristics of patients type 2 diabetes and coronavirus disease 2019 infection, with and without albuminuria

	Diabetic patients without baseline albuminuria, n = 45	Diabetic patients with baseline albuminuria, n = 20	P value
Age (yr), mean (SD)	58.7 (9.2)	62.2 (9.0)	0.16¹
Median (IQR)	60.0 (50.5-65.0)	63.0 (56.5-68.8)	0.16¹
Sex, female, n (%)	21 (46.7)	11 (55.0)	0.60²
Population group, n (%)			0.77²
Jews	13 (28.9)	7 (35.0)
Arabs	32 (71.1)	13 (65.0)
BMI (kg/m²), mean (SD)	31.6 (4.5)	33.2 (4.6)	0.19¹
Median (IQR)	30.9 (28.6-33.7)	32.3 (29.7-35.9)	0.19¹
Diabetes duration (yr), median (IQR)	10.0 (5.5-14.0)	11.0 (5.3-17.0)	0.25¹
eGFR (mL/min/1.73 m² body surface area) at baseline, median (IQR)	90.5 (77.8-99.5)	95.3 (69.6-101.1)	0.90³
HbA1c (%), median (IQR)	7.2 (6.6-8.4)	8.9 (7.3-10.4)	0.02³
Metformin, n (%)	41 (91.1)	15 (75)	0.12⁴
DPP-4 inhibitors, n (%)	15 (33.3)	3 (15)	0.15²
Sulfonylurea, n (%)	5 (11.1)	2 (10)	1.00⁴
SGLT2 inhibitors, n (%)	15 (33.3)	3 (15)	0.15²
GLP-1 agonists, n (%)	8 (17.8)	4 (20)	1.00⁴
Basal insulin, n (%)	8 (17.8)	10 (50)	0.015²
Prandial insulin, n (%)	2 (4.4)	4 (20)	0.067⁴
Current smoking, n (%)	2 (4.4)	2 (10)	0.58⁴
Retinopathy, n (%)	4 (12.9)	3 (20)	0.67⁴
NLR_max, median (IQR)	6.2 (2.5-9.4)	6.7 (2.6-18.0)	0.48³
CRP (mg/L) at admission, median (IQR)	90.4 (10.9-153.6)	43.9 (12.5-106.8)	0.33³
CRP_max (mg/L) at hospitalization, median (IQR)	92.8 (11.4-171.3)	61.0 (12.5-157.3)	0.60³
eGFR (mL/min/1.73 m² body surface area) at hospitalization, median (IQR)	90.3 (77.0-98.4)	94.3 (67.8-101)	0.76³
Albumin, median (IQR)	3.6 (3.3-4.0)	3.6 (3.1-3.9)	0.25¹

¹Independent sample t-test.

²Chi-square test.

³Mann-Whitney test.

⁴Fisher’s exact test.

IQR: Interquartile range; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; eGFR: Estimated glomerular filtration rate; DPP-4: Dipeptidyl-peptidase 4; SGLT2: Sodium/glucose cotransporter 2; GLP-1: Glucagon-like peptide 1; NLR_max: Maximum neutrophil:lymphocyte ratio; CRP: C-reactive protein; CRP_max: Maximum C-reactive protein.

Table 3 Clinical and demographic characteristics of patients with type 2 diabetes, with mild or moderate versus severe or critical coronavirus disease 2019 pneumonia

	Mild-moderate COVID-19 pneumonia, n = 34	Severe-critical COVID-19 pneumonia, n = 31	P value
Age (yr), mean (SD)	58.6 (10.0)	61.2 (8.1)	0.26¹
Median (IQR)	59.5 (50.8-65.3)	63 (57.0-67.0)	0.26¹
Sex, female, n (%)	20 (58.8)	12 (38.7)	0.14²
Population group, n (%)			1.00²
Jews	10 (29.4)	10 (32.3)
Arabs	24 (70.6)	21 (67.7)
BMI (kg/m²), mean (SD)	31.4 (3.8)	32.8 (5.2)	0.22¹
Median (IQR)	31.2 (28.9-33.6)	31.7 (29.3-36.1)	0.22¹
Diabetes duration (yr), median (IQR)	9.5 (4.8-12.5)	11 (7-17)	0.13³
eGFR (mL/min/1.73 m² body surface area) at baseline, median	90.4 (74.9-105.5)	93.3 (76.0-100.3)	0.78³
HbA1C (%), median (IQR)	7.4 (6.6-9.1)	7.4 (6.6-9.4)	0.93³
Metformin, n (%)	30 (88.2)	26 (83.9)	0.73⁴
DPP-4, n (%)	10 (29.4)	8 (25.8)	0.79²
Sulfonylurea, n (%)	5 (14.7)	2 (6.5)	0.43⁴
SGLT2 inhibitors, n (%)	11 (32.4)	7 (22.6)	0.42²
GLP-1 agonists, n (%)	5 (14.7)	7 (22.6)	0.53²
Basal insulin, n (%)	8 (23.5)	10 (32.3)	0.58²
Prandial insulin, n (%)	3 (8.8)	3 (9.7)	1.00⁴
Current smoking, n (%)	4 (11.8)	0 (0)	0.12⁴
No albuminuria, n (%)	21 (61.8)	24 (77.4)	0.19²
			2-sided
			0.14²
			1-sided
Albuminuria < 30 mg/g, n (%)	13 (38.2)	7 (22.6)	0.145³
Albuminuria < 30 mg/g, n (%)	13 (38.2)	7 (22.6)	2-sided
Albuminuria 30-300 mg/g, n (%)	8 (23.5)	6 (19.4)	0.073³
Albuminuria > 300 mg/g, n (%)	5 (14.7)	1 (3.2)	1-sided
Retinopathy, n (%)	4 (16.7)	3 (13.6)	1.00⁴
NLR_max median (IQR)	2.7 (1.7-8.5)	9.2 (5.7-15.4)	< 0.001³
CRP (mg/L) at admission, median (IQR)	15.4 (5.1-80.9)	122.1 (70.8-177.2)	< 0.001³
CRP_max (mg/L) at hospitalization, median (IQR)	15.4 (5.1-86.2)	142.3 (87.1-205.1)	< 0.001³
eGFR (mL/min/1.73 m² body surface area) at hospitalization, median (IQR)	91.2 (76.0-105.0)	93.3 (76.5-100.3)	0.90³
Albumin (g/dL), mean (SD)	3.8 (0.4)	3.3 (0.4)	< 0.001¹
Median (IQR)	3.9 (3.6-4.1)	3.3 (3.1-3.5)	< 0.001¹

¹Independent sample t-test.

²Chi-square test.

³Mann-Whitney test.

⁴Fisher’s exact test.

Table 4 Multivariable logistic regression analysis performed to determine the risk factors for severe coronavirus disease 2019 infection (n = 65)

		OR	95%CI	P value
Model 1	Sex (female vs male)	0.30	0.10-0.93	0.038
Baseline characteristics	Age (yr)	1.03	0.98-1.09	0.28
R-square: 14.4%	BMI (kg/m²)	1.12	0.99-1.28	0.073
Model 2	Sex (female vs male)	0.57	0.15-2.16	0.41
Baseline characteristics	Age (yr)	1.02	0.94-1.11	0.62
R-square: 34.4%	BMI (kg/m²)	1.14	0.96-1.35	0.13
	HbA1c (%)	0.85	0.59-1.23	0.39
	Baseline eGFR (mL/min/ 1.73 m² of body surface area)	1.02	0.98-1.07	0.28
	NLR_max	1.18	1.05-1.33	0.007
Model 3	Sex (female vs male)	0.42	0.09-1.94	0.27
Baseline characteristics	Age (yr)	1.08	0.97-1.20	0.18
R-square = 46.9%	BMI (kg/m²)	1.24	1.01-1.53	0.040
	HbA1c (%)	1.04	0.67-1.61	0.89
	Baseline eGFR (mL/min/1.73 m² of body surface area)	1.04	0.99-1.09	0.12
	NLR_max	1.20	1.06-1.37	0.005
	Albuminuria	0.09	0.01-0.62	0.015

OR: Odds ratio; CI: Confidence intervals; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; eGFR: Estimated glomerular filtration rate; NLR_max: Maximum neutrophil:lymphocyte ratio; CRP: C-reactive protein; IQR: Interquartile range.

Table 5 Multivariable logistic regression analysis performed to determine the risk factors for bacterial infection (n = 144)

		OR	95%CI	P value
Model 1	Sex (female vs male)	1.88	0.70-5.05	0.21
Baseline characteristics	Age (yr)	0.98	0.93-1.02	0.34
R-square: 2.8%	BMI (kg/m²)	0.95	0.88-1.04	0.27
Model 2	Sex (female vs male)	7.23	1.57-33.23	0.011
Baseline characteristics	Age (yr)	1.00	0.92-1.09	0.97
R-square: 54.0%	BMI (kg/m²)	0.94	0.84-1.05	0.26
	HbA1c (%)	1.19	0.88-1.60	0.25
	Baseline eGFR (mL/min/1.73 m² of body surface area)	1.05	1.01-1.08	0.013
	NLR_max	1.36	1.21-1.54	< 0.001
Model 3	Sex (female vs male)	7.26	1.58-33.44	0.011
Baseline characteristics	BMI (kg/m²)	0.94	0.84-1.05	0.26
R-square: 54.0%	Age (yr)	1.00	0.92-1.09	0.98
	HbA1c (%)	1.19	0.87-1.61	0.28
	Baseline eGFR (mL/min/1.73 m² of body surface area)	1.05	1.01-1.08	0.012
	NLR_max	1.37	1.21-1.55	< 0.001
	Albuminuria	1.12	0.32-3.96	0.86

OR: Odds ratio; CI: Confidence intervals; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; eGFR: Estimated glomerular filtration rate; NLR_max: Maximum neutrophil:lymphocyte ratio.

Citation: Bashkin A, Shehadeh M, Shbita L, Namoura K, Haiek R, Kuyantseva E, Boulos Y, Yakir O, Kruzel-Davila E. Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia. World J Diabetes 2022; 13(12): 1154-1167
URL: https://www.wjgnet.com/1948-9358/full/v13/i12/1154.htm
DOI: https://dx.doi.org/10.4239/wjd.v13.i12.1154